SLC25A1抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P01804(SLC25A1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P01804(SLC25A1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The SLC25A1 antibody is a research tool designed to detect the solute carrier family 25 member 1 (SLC25A1), a mitochondrial carrier protein critical for cellular metabolism. SLC25A1. also known as the citrate transport protein (CTP), facilitates the exchange of citrate and isocitrate across the mitochondrial inner membrane, linking the tricarboxylic acid (TCA) cycle with cytosolic pathways for fatty acid synthesis, gluconeogenesis, and neurotransmitter synthesis. Dysregulation of SLC25A1 is implicated in metabolic disorders, cancer, and neurological diseases, making it a target for mechanistic and therapeutic studies.

The antibody is typically developed using immunogenic peptides or recombinant protein fragments of SLC25A1. often validated in applications like Western blotting, immunohistochemistry, and immunofluorescence. It aids in assessing protein expression levels, subcellular localization, and interactions in various tissues or cell lines. Specificity is confirmed through knockdown/knockout controls or blocking assays.

Research utilizing SLC25A1 antibodies has advanced understanding of its role in metabolic reprogramming in cancers, such as its overexpression in tumors reliant on citrate for lipid biosynthesis. Additionally, studies link SLC25A1 mutations to severe developmental disorders, including combined D-2- and L-2-hydroxyglutaric aciduria. Commercial antibodies vary in host species (e.g., rabbit, mouse) and clonality, with selection depending on experimental needs. Proper validation ensures reliability in uncovering SLC25A1’s pathophysiological significance and therapeutic potential.